New Legislation Will Address Oncology Prescription Drug Shortages
February 9th 2011A new law, introduced by Senators Amy Klobuchar (D-Minnesota) and Bob Casey (D-Pennsylvania), will require prescription drug manufacturers to give the US Food and Drug Administration (FDA) early warning of anything that will likely result in a drug shortage.
FDA Denies Approval for Avodart for Prostate Cancer Prevention
February 1st 2011The GlaxoSmithKline (GSK) drug Avodart (dutasteride), already approved for treatment in men with enlarged prostate glands, has been rejected by the FDA for the additional indication of reducing the risk of prostate cancer.
Comparative Effectiveness Research and Health Reform
January 28th 2011A recent analysis in the Cancer Journal outlines the various effects of last year's landmark health care reform bill on cancer research. Some positive changes will be in the pipeline as will some potentially negative unanticipated consequences.
EHRs and Meaningful Use: The Ongoing Debate
January 27th 2011Recent data from the National Center for Health Statistics (NCHS) shows that an increasing number of primary care physicians have already adopted a basic EHR, but most physicians would need to further upgrade their EHR systems or their use of the systems in order to qualify for “meaningful use” incentive payments.
ASCO Issues New End-of-Life Policy Statement and Patient Guide
January 26th 2011ASCO’s QOPI analysis recently found that less than half of all cancer patients are enrolled in hospice care before their death and of those who are enrolled, one-third are not enrolled until the last week of their lives. In response to this and other findings, ASCO published a new policy and guidelines this week, intended to encourage physicians to initiate open dialogue about palliative care and treatment with patients as soon as they are identified as having incurable cancer.
Implementing EHRs in Community Oncology Practices
January 19th 2011To provide quality healthcare, communication is vital. Using an EHR, physicians can more easily communicate regarding current and past medical conditions with other providers in their practice, with referring or co-managing physicians, and with patients themselves.
NIH Study Predicts the Cost of Cancer Care will Increase 27% by 2020
January 13th 2011According to a recent analysis by researchers at the National Cancer Institute, in 2020, medical expenditures for cancer should reach at least $158 billion (in 2010 dollars). This represents an increase of 27 percent over 2010.
New Kinome Database Promises Wealth of Unexpected Cancer Drug Targets
January 5th 2011"Kinome" is the word to know this year in oncology, because it has begun to reveal molecules that some tumors are relying on to survive, which until now we had no idea were involved in cancer or which we hardly knew at all.
JAK inhibitor quells symptoms linked to myelofibrosis
December 30th 2010Patients with myelofibrosis experienced relief from pain, fatigue, and other symptoms associated with enlarged spleens after treatment with a JAK1 and JAK2 inhibitor, according to study results from Houston’s M.D. Anderson Cancer Center.
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
December 30th 2010Jeff Kranau’s story is a moving one but, during this economic downturn, not necessarily a unique one. The former South Florida salesman was successfully treated for squamous cell carcinoma of the larynx in 2009 and declared cancerfree. But what should have been a reason for celebration has, over time, sent Mr. Kranau’s life into a tailspin.
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
December 30th 2010Like the protective plastic cap at the ends of shoelaces that prevent them from unraveling, telomeres protect the ends of chromosomes. These small strips of DNA prevent chromosome tips from fraying during cell division. But as the cells divide, the telomeres shorten and the cells age. Shortened telomeres have been linked to an increased risk of cancer development. Researchers at the Mayo Clinic in Rochester, Minn., wanted to see if telomere shortening was linked to colon cancer development at a younger age.
Postgastrectomy Patients May Benefit From HP Eradication Rx
December 29th 2010After resection for cancer or peptic ulcer disease, the mucosa of the gastric stump is considered prone to the development of gastric cancer precursor lesions (see Fact box), most likely because of exposure to Helicobacter pylori infection. Italian researchers set out to determine if the risk of gastric cancer recurrence was greater in the stump in the presence of HP infection.
Early Engagement by Healthcare Professionals Helps Overcome Public Skepticism About Biobanking
December 29th 2010Enlivening the public discussion about cancer biobanking will speed up the collection of specimens for research supporting the goal of personalized medicine. Biobanking is particularly important in minority populations, who experience a disproportionally greater burden of cancer incidence and mortality. But rather than unilaterally creating and launching a public education program, community medicine specialists in Florida first solicited public input.
McKesson Expands in Oncology With $2 Billion Acquisition
December 29th 2010One of the world's largest providers of medical services and information technologies sees strong growth in oncology services in the coming years, growth that can be leveraged into profits with the right blend of productivity and cost efficiency tools. With this in mind, McKesson plans to spend more than $2 billion to purchase the largest community-based cancer treatment and research network in America.
Minority Accrual to Trials Calls for Aggressive Strategies
December 29th 2010A program initiated at the Dan. L. Duncan Cancer Center in Houston, Texas, raised the participation of African-American and Hispanic patients in clinical trials to levels that approached that of the general population of the center's catchment area.
Next gen EGFR targeting drug promising in NSCLC
December 29th 2010Finding an effective treatment for all the complex iterations of cancer is akin to chasing an outlaw through a treacherous mountain range, in the estimation of Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.
Best of the Society for Integrative Oncology: 2010
December 22nd 2010NEW YORK-Turkey tail, healing touch, and liquidambar stryraciflua are areas in complementary medicine that are worth keeping an eye on, according to integrative oncology experts. The Society for Integrative Oncology (SIO) named five abstracts as its best during its 2010 meeting.
Myth Busting: Does Real-World Experience Lead to Better Drug Choices?
December 15th 2010In the era of evidence-based medicine, clinical guidelines, and personalized medicine, one would think that convincing clinical trial data would influence clinical practice if disseminated in an appropriate manner. However, it has been estimated that only 50% of current medical practice is evidence-based, clearly demonstrating a compelling need to collect and analyze additional data to better inform practice. Current data are usually gathered from a variety of sources, including clinical trials, observational studies, and meta-analyses. Yet according to Jeff Forringer, CEO of IntrinsiQ, data from oncology practices provide real-world outcomes that give better insight into the efficacy of cancer therapeutics.